Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593125 · ClinicalTrials.gov registry record · Phase 2
Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00593125 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 15 participants.
The verdict
NCT00593125, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The proposed investigation will use methadone maintained patients who have concurrent cocaine dependence in order to take advantage of the excellent (over 80%) treatment retention in this patient group and to maximize treatment compliance by daily observed medication with both methadone and levetiracetam. In the initial patients we will explore the tolerability of escalating doses of levetiracetam as well as its potential role in reducing cocaine use, as monitored by self-report and verified by three-times weekly urine toxicology testing in methadone treated patients.The specific aim of this study is to evaluate the tolerability and efficacy of levetiracetam 3 grams/day in modifying cocaine-using behavior, reducing cocaine craving and attenuating cocaine's reinforcing effect among methadone-maintained patients
Interventions
- DRUG levetiracetam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00593125
The ClinicalTrials.gov registry entry for NCT00593125 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which levetiracetam is the first listed.
NCT00593125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00593125 about?
NCT00593125 is a clinical study titled "Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.". The proposed investigation will use methadone maintained patients who have concurrent cocaine dependence in order to take advantage of the excellent (over 80%) treatment retention in this patient group and to maximize treatment compliance by daily observed medication with both methadone and levetira...
What is the current status of trial NCT00593125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00593125?
The interventions under investigation include: levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00593125?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.